Skip to main content

Advertisement

SpringerLink
Log in

Putative effects of potentially anti-angiogenic drugs in rheumatic diseases

  • Review Article
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

A role for angiogenesis has been described in several rheumatic diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, systemic sclerosis, systemic lupus erythematosus, vasculitides, and osteoarthritis, leading to the possibility that angiogenesis inhibition may be an additional useful therapeutic arm. While the role of anti-angiogenic therapy in rheumatoid arthritis has received attention, it is conceivable that the inhibition of pathological angiogenesis may also be a useful therapeutical approach in other rheumatic diseases. Numerous compounds, such as, for example, various interleukins, antibodies directed against angiogenic factors, peptides, estrogen metabolites, disease-modifying anti-rheumatic drugs, have been found to have anti-angiogenic properties. However, additional research is needed to obtain a clear understanding of the pathogenic mechanism of angiogenesis and the potential applications of anti-angiogenic therapy in rheumatic diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364

    Article  CAS  PubMed  Google Scholar 

  2. Koch AE (2000) The role of angiogenesis in rheumatoid arthritis: recent developments. Ann Rheum Dis 59:i65–i71

    Article  PubMed  Google Scholar 

  3. Szekanecz Z, Koch AE (2009) Angiogenesis and its targeting in rheumatoid arthritis. Vascul Pharmacol 51:1–7

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Takahara K, Iioka T, Furukawa K, Uchida T, Nakashima M, Tsukazaki T, Scindo H (2004) Autocrine/paracrine role of the angiopoietin-1 and −2/Tie2 system in cell proliferation and chemotaxis of cultured fibroblastic synoviocytes in rheumatoid arthritis. Hum Pathol 35:150–158

    Article  CAS  PubMed  Google Scholar 

  5. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR (1999) Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 103:341–345

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Levy NS, Chung S, Furneaux H, Levy AP (1998) Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 273:6417–6423

    Article  CAS  PubMed  Google Scholar 

  7. Park YW, Mo Kang Y, Butterfield J, Detmar M, Goronzy JJ, Weyand CM (2004) Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis. Am J Pathol 165:2087–2098

    Article  CAS  PubMed  Google Scholar 

  8. Yamamoto T (2013) Angiogenic and inflammatory properties of psoriatic arthritis. ISRN Dermatol 2013:630620

    Article  PubMed Central  PubMed  Google Scholar 

  9. Szekanecz Z, Koch AE (2007) Mechanism of disease: angiogenesis in inflammatory diseases. Nat Clin Pract Rheumatol 3:635–643

    Article  CAS  PubMed  Google Scholar 

  10. Manetti M, Guiducci S, Ibba-Manneschi L, Matucci-Cerinic M (2011) Impaired angiogenesis in systemic sclerosis: the emerging role of the antiangiogenic VEGF(165)b splice variant. Trends Cardiovasc Med 21:204–210

    Article  CAS  PubMed  Google Scholar 

  11. Manetti M, Guiducci S, Romano E, Ceccarelli C, Bellando-Randone S, Conforti ML, Ibba-Manneschi L, Matucci-Cerinic M (2011) Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ Res 109:e14–26

    Article  CAS  PubMed  Google Scholar 

  12. Hernández-Rodríguez J, García-Martínez A, Casademont J, Filella X, Esteban MJ, López-Soto A, Fernández-Solà J, Urbano-Márquez A, Grau JM, Cid MC (2002) A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum 47:29–35

    Article  PubMed  Google Scholar 

  13. Halacheva K, Gulubova MV, Manolova I, Petkov D (2002) Expression of ICAM-1, VCAM-1, E-selectin and TNF-alpha on the endothelium of femoral and iliac arteries in thromboangiitis obliterans. Acta Histochem 104:177–184

    Article  CAS  PubMed  Google Scholar 

  14. Bodolay E, Koch AE, Kim J, Szegedi G, Szekanecz Z (2002) Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. J Cell Mol Med 6:357–376

    Article  CAS  PubMed  Google Scholar 

  15. Yacin B, Arda N, Tezel GG, Erman M, Alli N (2006) Expressions of vascular endothelial growth factor and CD34 in oral aphthous lesions of Behcet’s disease. Anal Quant Cytol Histol 28:303–306

    Google Scholar 

  16. Bonnet CS, Walsh DA (2005) Osteoarthritis, angiogenesis and inflammation. Rheumatology (Oxford) 44:7–16

    Article  CAS  Google Scholar 

  17. Goedkoop AY, Kraan MC, Picavet DI, de Rie MA, Teunissen MB, Bos JD, Tak PP (2004) Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther 6:R326–R334

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Markham T, Mullan R, Golden-Mason L, Rogers S, Bresnihan B, Fitzgerald O, Fearon U, Veale DJ (2006) Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. J Am Acad Dermatol 54:1003–1012

    Article  PubMed  Google Scholar 

  19. Chen Y, Donnelly E, Kobayashi H, Debusk LM, Lin PC (2005) Gene therapy targeting the Tie2 function ameliorates collagen-induced arthritis and protects against bone destruction. Arthritis Rheum 52:1585–1594

    Article  CAS  PubMed  Google Scholar 

  20. Koch AE (2003) Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis 62:ii60–ii67

    Article  CAS  PubMed  Google Scholar 

  21. D’Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082–4085

    Article  PubMed  Google Scholar 

  22. Versapuech J, Beylot-Barry M, Doutre MS, Beylot C (2000) Subacute cutaneous lupus. Evolutive and therapeutic features of a series of 24 cases. Presse Med 29:1596–1599

    CAS  PubMed  Google Scholar 

  23. Brik R, Shamali H, Bergman R (2001) Successful thalidomide treatment of severe infantile Behçet disease. Pediatr Dermatol 18:143–145

    Article  CAS  PubMed  Google Scholar 

  24. Ribatti D, Vacca A (2005) Therapeutic renaissance of thalidomide in the treatment of haematological malignancies. Leukemia 19:1525–1531

    Article  CAS  PubMed  Google Scholar 

  25. Siegle I, Klein T, Backman JT, Saal JG, Nusing RM, Fritz P (1998) Expression of cyclooxygenase-2 in human synovial tissue. Arthritis Rheum 41:122–129

    Article  CAS  PubMed  Google Scholar 

  26. Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, Croxtall J, Willoughby DA (1994) Inducible isoforms of cyclooxygenase and nitric oxide synthase in inflammation. Proc Natl Acad Sci USA 91:2046–2050

    Article  CAS  PubMed  Google Scholar 

  27. Woods JM, Mogollon A, Amin MA, Martinez RJ, Koch AE (2003) The role of COX-2 in angiogenesis and rheumatoid arthritis. Exp Mol Pathol 74:282–290

    Article  CAS  PubMed  Google Scholar 

  28. Eliceiri BP, Cheresh DA (1998) The role of alphav integrins during angiogenesis. Mol Med 4:741–750

    CAS  PubMed Central  PubMed  Google Scholar 

  29. Takahashi H, Kato K, Miyake K, Hirai Y, Yoshino S, Shimada T (2005) Adeno-associated virus vector-mediated anti-angiogenic gene therapy for collagen-induced arthritis in mice. Clin Exp Rheumatol 23:455–461

    CAS  PubMed  Google Scholar 

  30. Yue L, Shen YX, Feng LJ, Chen FH, Yao HW, Liu LH, Wu Q, Wang H (2007) Blockage of the formation of new blood vessels by recombinant human endostatin contributes to the regression of rat adjuvant arthritis. Eur J Pharmacol 567:166–170

    Article  CAS  PubMed  Google Scholar 

  31. Yamaguchi Y, Takihara T, Chambers RA, Veraldi KL, Larregina AT, Feghali-Bostwick CA (2012) A peptide derived from endostatin ameliorates organ fibrosis. Sci Transl Med 4(136):136ra71

    Article  CAS  PubMed  Google Scholar 

  32. Wang CR, Chen SY, Shiau AL, Wu CL, Jou IM, Chao L, Chao J (2007) Upregulation of kallistatin expression in rheumatoid joints. J Rheumatol 34:2171–2176

    CAS  PubMed  Google Scholar 

  33. Wang CR, Chen SY, Wu CL, Liu MF, Jin YT, Chao L, Chao J (2005) Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum 52:1319–1324

    Article  CAS  PubMed  Google Scholar 

  34. Rico MC, Castaneda JL, Manns JM, Uknis AB, Sainz IM, Safadi FF, Popoff SN, Dela Cadena RA (2007) Amelioration of inflammation, angiogenesis and CTGF expression in an arthritis model by a TSP-1-derived peptide treatment. J Cell Physiol 211:504–512

    Article  CAS  PubMed  Google Scholar 

  35. Bessis N, Boissier MC (1998) Gene therapy in rheumatoid polyarthritis: perspectives. Presse Med 27:580–582

    CAS  PubMed  Google Scholar 

  36. Saito M, Murata T, Watanabe K et al (2005) Adenoviral vector-mediated gene transfer of IL-13R_2 chain followed by IL-13 cytotoxin treatment offers potent targeted therapy for cytotoxin-resistant cancers. Int J Cancer 116:1–8

    Article  CAS  PubMed  Google Scholar 

  37. Haas CS, Amin MA, Allen BB, Ruth JH, Haines GK III, Woods JM, Koch AE (2006) Inhibition of angiogenesis by interleukin-4 gene therapy in rat adjuvant-induced arthritis. Arthritis Rheum 54:2402–2414

    Article  CAS  PubMed  Google Scholar 

  38. Haas CS, Amin MA, Ruth JH, Allen BL, Ahmed S, Pakozdi A, Woods JM, Shahrara S, Koch AE (2007) In vivo inhibition of angiogenesis by interleukin-13 gene therapy in a rat model of rheumatoid arthritis. Arthritis Rheum 56:2535–2548

    Article  CAS  PubMed  Google Scholar 

  39. Afuwape AO, Feldmann M, Paleolog EM (2003) Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis. Gene Ther 10:1950–1960

    Article  CAS  PubMed  Google Scholar 

  40. Carmeliet P, Ferreira V, Breier G et al (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435–439

    Article  CAS  PubMed  Google Scholar 

  41. Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5:761–772

    Article  CAS  PubMed  Google Scholar 

  42. Kaur G, Belotti D, Burger AM et al (2004) Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res 10:4813–4821

    Article  CAS  PubMed  Google Scholar 

  43. Liu YV, Baek JH, Zhang H, Diez R, Cole RN, Semenza GL (2007) RACK1 competes with HSP90 for binding to HIF-1α and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1α. Mol Cell 25:207–217

    Article  PubMed Central  PubMed  Google Scholar 

  44. Sun J, Liao JK (2004) Induction of angiogenesis by heat shock protein 90 mediated by protein kinase Akt and endothelial nitric oxide synthase. Arterioscler Thromb Vasc Biol 24:2238–2244

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  45. Nagy G, Koncz A, Telarico T, Fernandez D, Ersek B, Buzás E, Perl A (2010) Central role of nitric oxide in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther 12:210

    Article  PubMed Central  PubMed  Google Scholar 

  46. Jhaveri K, Taldone T, Modi S, Chiosis G (2012) Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 1823:742–755

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Rice JW, Veal JM, Fadden RP, Barabasz AF, Partridge JM, Barta TE, Dubois LG, Huang KH, Mabbett SR, Silinski MA, Steed PM, Hall SE (2008) Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis. Arthritis Rheum 58:3765–3775

    Article  CAS  PubMed  Google Scholar 

  48. Ireson CR, Chander SK, Purohit A, Perera S, Newman SP, Parish D et al (2004) Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents. Br J Cancer 90:932–937

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  49. Khong TL, Larsen H, Raatz Y, Paleolog E (2007) Angiogenesis as a therapeutic target in arthritis: learning the lessons of the colorectal cancer experience. Angiogenesis 10:243–258

    Article  CAS  PubMed  Google Scholar 

  50. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG (1972) Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56:95–101

    CAS  PubMed  Google Scholar 

  51. Jackson JK, Higo T, Hunter WL, Burt HM (2008) Topoisomerase inhibitors as anti-arthritic agents. Inflamm Res 57:126–134

    Article  CAS  PubMed  Google Scholar 

  52. Koo OM, Rubinstein I, Onyüksel H (2011) Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis. Pharm Res 28:776–787

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  53. Pache M, Schwarz HA, Kaiser HJ, Wuest P, Kloti M, Dubler B, Flammer J (2002) Elevated plasma endothelin-1 levels and vascular dysregulation in patients with rheumatoid arthritis. Med Sci Monit 8:CR616–CR619

    CAS  PubMed  Google Scholar 

  54. Julkunen H, Saijonmaa O, Gronhagen-Riska C, Teppo AM, Fyhrquist F (1991) Raised plasma concentrations of endothelin-1 in systemic lupus erythematosus. Ann Rheum Dis 50:526–527

    Article  CAS  PubMed  Google Scholar 

  55. Melendez AJ (2008) Sphingosine kinase signalling in immune cells: potential as novel therapeutic targets. Biochim Biophys Acta 1784:66–75

    Article  CAS  PubMed  Google Scholar 

  56. Kitano M, Hla T, Sekiguchi M, Kawahito Y, Yoshimura R, Miyazawa K, Iwasaki T, Sano H, Saba JD, Tam YY (2006) Sphingosine 1-phosphate/sphingosine 1-phosphate receptor 1 signaling in rheumatoid synovium: regulation of synovial proliferation and inflammatory gene expression. Arthritis Rheum 54:742–753

    Article  CAS  PubMed  Google Scholar 

  57. Matsuura M, Imayoshi T, Chiba K, Okumoto T (2000) Effect of FTY720, a novel immunosuppressant, on adjuvant-induced arthritis in rats. Inflamm Res 49:404–410

    Article  CAS  PubMed  Google Scholar 

  58. Sheikh A, Naqvi SH, Naqvi SH, Sheikh K (2012) Itraconazole: its possible role in inhibiting angiogenesis in rheumatoid arthritis. Med Hypotheses 79:313–314

    Article  CAS  PubMed  Google Scholar 

  59. Aftab BT, Dobromilskaya I, Liu JO, Rudin CM (2011) Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer Res 71:6764–6772

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  60. Bainbridge J, Sivakumar B, Paleolog E (2006) Angiogenesis as a therapeutic target in arthritis: lessons from oncology. Curr Pharm Des 12:2631–2644

    Article  CAS  PubMed  Google Scholar 

Download references

Competing interests

None.

Author information

Authors and Affiliations

  1. Rheumatology Clinic, Department of Medical and Surgical Sciences, University of Foggia Medical School, Foggia, Italy

    Nicola Maruotti & Francesco Paolo Cantatore

  2. Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, Italy

    Domenico Ribatti

  3. Rheumatology Clinic “Mario Carrozzo”, “D’Avanzo” Hospital, Viale degli Aviatori, 1, 71100, Foggia, Italy

    Francesco Paolo Cantatore

Authors
  1. Nicola Maruotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesco Paolo Cantatore
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Domenico Ribatti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesco Paolo Cantatore.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maruotti, N., Cantatore, F.P. & Ribatti, D. Putative effects of potentially anti-angiogenic drugs in rheumatic diseases. Eur J Clin Pharmacol 70, 135–140 (2014). https://doi.org/10.1007/s00228-013-1605-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-013-1605-6

Keywords

Search

Navigation